Jade Biosciences Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Jade Biosciences (Nasdaq: JBIO) priced a public offering of 10,000,000 common shares at $15.00 per share, for expected gross proceeds of $150 million before expenses. Underwriters have a 30-day option for up to 1,500,000 extra shares.

According to Jade Biosciences, net proceeds plus existing cash will fund clinical trials, preclinical studies, manufacturing, R&D, capital expenditures, working capital and general corporate purposes. The offering is expected to close on June 5, 2026, subject to customary conditions.

Positive

• Public equity raise targeting gross proceeds of approximately $150 million
• Option for underwriters to buy up to 1,500,000 additional shares
• Proceeds earmarked to fund clinical trials and preclinical studies
• Capital to support manufacturing, R&D, working capital and corporate uses

Negative

• Issuance of 10,000,000 new shares creates potential shareholder dilution
• Underwriters’ 1,500,000-share option could increase total dilution further

News Market Reaction – JBIO

+0.85%

5 alerts

+0.85% Session close to close

+19.4% Peak Tracked

-7.5% Trough Tracked

$875.64M Market Cap

0.1x Rel. Volume

In the Jun 4 session, JBIO gained 0.85%, reflecting a mild positive market reaction. Argus tracked a peak move of +19.4% during that session. Argus tracked a trough of -7.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a fully marketed equity raise of 10,000,000 common shares at $15.00, for g...

Analysis

This announcement details a fully marketed equity raise of 10,000,000 common shares at $15.00, for gross proceeds of $150.0 million plus a 1,500,000-share underwriters’ option. The deal uses an already effective Form S-3 shelf, with closing expected on June 5, 2026. In context of recent positive clinical updates and prior cash of $311.3 million, key considerations include dilution from new shares and how efficiently proceeds advance Phase 1 and Phase 2 programs.

Key Figures

Shares offered: 10,000,000 shares Offer price: $15.00 per share Gross proceeds: $150.0 million +5 more

8 metrics

Shares offered 10,000,000 shares Public offering of common stock

Offer price $15.00 per share Public offering pricing

Gross proceeds $150.0 million Before underwriting fees and expenses

Underwriters’ option period 30 days Period to purchase additional shares

Additional option shares 1,500,000 shares Underwriters’ over-allotment option

Expected closing date June 5, 2026 Scheduled closing of offering

Current share price $17.59 Pre-offering market price from context data

52-week range $6.565–$28.00 Pre-offering trading range

Historical Context

5 past events · Latest: Jun 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Phase 1 interim data	Positive	-11.6%	Positive interim Phase 1 JADE101 data with ~70% IgA reduction.
May 29	Conference call setup	Positive	-11.6%	Announcement of call to discuss interim Phase 1 JADE101 results.
May 26	Phase 1 trial start	Positive	-1.0%	First participant dosed in Phase 1 trial of JADE201 for autoimmune use.
May 26	Phase 2 trial start	Positive	-2.3%	First participant dosed in JUNIPER Phase 2 trial of JADE101 in IgAN.
May 07	Q1 2026 earnings	Positive	+6.6%	Q1 results and cash of $311.3M indicating funding into first half 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent JBIO news has often been followed by negative price reactions even on seemingly positive clinical updates, while the latest earnings update saw a positive move.

Recent Company History

Over the past month, JBIO has reported multiple clinical milestones, including first dosing in Phase 1 and Phase 2 trials and positive interim Phase 1 data for JADE101. Despite these updates, shares fell after several clinical announcements, such as the -11.64% reaction on Jun 1, 2026. In contrast, Q1 2026 results on May 7, 2026, highlighting $311.3 million in cash and investments, coincided with a 6.56% gain. Against this backdrop, the current financing fits a pattern of active capital-raising during an intensive development phase.

Key Terms

public offering, common stock, underwriters’ option, underwriting discounts and commissions, +4 more

8 terms

public offering financial

"announced the pricing of a public offering of 10,000,000 shares"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

common stock financial

"public offering of 10,000,000 shares of its common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

underwriters’ option financial

"granted the underwriters a 30-day option to purchase up to an additional"

An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.

underwriting discounts and commissions financial

"before deducting the underwriting discounts and commissions and other"

Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3, including a base"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to a shelf registration statement on Form S-3, including a base"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

book-running managers financial

"Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $150.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 5, 2026, subject to the satisfaction of customary closing conditions. In addition, Jade has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock to be sold in the public offering are being sold by Jade.

Jade intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and investments, to fund clinical trials, preclinical studies, and manufacturing in support of its programs, as well as for additional research and development activities, capital expenditures, working capital and other general corporate purposes.

Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers for the offering. LifeSci Capital is acting as passive book-running manager for the offering. BTIG is acting as a lead manager for the offering.

The securities described above are being offered by Jade pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on May 15, 2026. A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. The offering may be made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; and UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, or by email at ol-prospectus-request@ubs.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Forward Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, our expectations regarding the expected closing of the offering and the anticipated use of net proceeds therefrom. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its subsequent filings). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.

Jade Biosciences Contact

Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134

FAQ

What did Jade Biosciences (JBIO) announce about its June 2026 stock offering?

Jade Biosciences announced a public offering of 10,000,000 common shares at $15.00 per share. According to Jade Biosciences, this offering is expected to generate about $150 million in gross proceeds before underwriting discounts, commissions and other offering expenses.

How much capital will Jade Biosciences (JBIO) raise from its June 2026 stock sale?

Jade Biosciences expects gross proceeds of approximately $150 million from the offering. According to Jade Biosciences, this is based on selling 10,000,000 common shares at $15.00 each, excluding any exercise of the underwriters’ option to purchase additional shares.

What is the size and structure of the Jade Biosciences (JBIO) June 2026 equity offering?

The offering consists of 10,000,000 common shares at $15.00 per share, all sold by Jade Biosciences. According to Jade Biosciences, underwriters also hold a 30-day option to purchase up to 1,500,000 additional shares at the public offering price, less discounts.

When is the Jade Biosciences (JBIO) public offering expected to close?

The stock offering is expected to close on June 5, 2026. According to Jade Biosciences, completion of the transaction remains subject to the satisfaction of customary closing conditions typically associated with underwritten public offerings of common stock.

How will Jade Biosciences (JBIO) use proceeds from its June 2026 stock offering?

Jade Biosciences plans to use net proceeds, with existing cash, to fund clinical trials, preclinical studies and manufacturing. According to Jade Biosciences, remaining funds will support additional R&D, capital expenditures, working capital and general corporate purposes for its autoimmune programs.

Which banks are managing the Jade Biosciences (JBIO) June 2026 stock offering?

Jefferies, TD Cowen and UBS Investment Bank act as joint book-running managers for the offering. According to Jade Biosciences, LifeSci Capital serves as passive book-running manager, and BTIG participates as lead manager in the underwritten common stock transaction.